相似文献
1
RNF43: A Biomarker With Potential Ramifications for Therapeutic Intervention in Gastric Cancer.
Cell Mol Gastroenterol Hepatol. 2021;11(4):1202-1203. doi: 10.1016/j.jcmgh.2020.11.014. Epub 2020 Dec 19.
2
Loss of endogenous RNF43 function enhances proliferation and tumour growth of intestinal and gastric cells.
Carcinogenesis. 2019 Jun 10;40(4):551-559. doi: 10.1093/carcin/bgy152.
3
Ring finger protein 43 associates with gastric cancer progression and attenuates the stemness of gastric cancer stem-like cells via the Wnt-β/catenin signaling pathway.
Stem Cell Res Ther. 2017 Apr 26;8(1):98. doi: 10.1186/s13287-017-0548-8.
4
A phospho-switch controls RNF43-mediated degradation of Wnt receptors to suppress tumorigenesis.
Nat Commun. 2020 Sep 15;11(1):4586. doi: 10.1038/s41467-020-18257-3.
5
RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis.
Oncotarget. 2016 Oct 25;7(43):70589-70600. doi: 10.18632/oncotarget.12130.
6
Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma.
Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):12649-54. doi: 10.1073/pnas.1307218110. Epub 2013 Jul 11.
7
Roles of E3 ubiquitin ligases in gastric cancer carcinogenesis and their effects on cisplatin resistance.
J Mol Med (Berl). 2021 Feb;99(2):193-212. doi: 10.1007/s00109-020-02015-5. Epub 2021 Jan 3.
8
Post-translational Wnt receptor regulation: Is the fog slowly clearing?: The molecular mechanism of RNF43/ZNRF3 ubiquitin ligases is not yet fully elucidated and still controversial.
Bioessays. 2021 Apr;43(4):e2000297. doi: 10.1002/bies.202000297. Epub 2021 Feb 11.
9
Protease associated domain of RNF43 is not necessary for the suppression of Wnt/β-catenin signaling in human cells.
Cell Commun Signal. 2020 Jun 11;18(1):91. doi: 10.1186/s12964-020-00559-0.
10
Dysregulated Wnt signalling and recurrent mutations of the tumour suppressor RNF43 in early gastric carcinogenesis.
J Pathol. 2016 Nov;240(3):304-314. doi: 10.1002/path.4777.
引用本文的文献
1
Modeling human gastric cancers in immunocompetent mice.
Cancer Biol Med. 2024 Jun 28;21(7):553-70. doi: 10.20892/j.issn.2095-3941.2024.0124.
2
Development and verification of a microsatellite instability-related risk signature for predicting survival and therapy effectiveness in gastric cancer.
J Gastrointest Oncol. 2022 Feb;13(1):84-101. doi: 10.21037/jgo-21-808.
3
WNT/β-Catenin Pathway in Soft Tissue Sarcomas: New Therapeutic Opportunities?
Cancers (Basel). 2021 Nov 3;13(21):5521. doi: 10.3390/cancers13215521.
4
Differences in Somatic Mutation Profiles between Korean Gastric Cancer and Gastric Adenoma Patients.
J Clin Med. 2021 May 10;10(9):2038. doi: 10.3390/jcm10092038.
本文引用的文献
1
Loss of RNF43 Function Contributes to Gastric Carcinogenesis by Impairing DNA Damage Response.
Cell Mol Gastroenterol Hepatol. 2021;11(4):1071-1094. doi: 10.1016/j.jcmgh.2020.11.005. Epub 2020 Nov 11.
2
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
3
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6.
4
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes.
Nat Med. 2015 May;21(5):449-56. doi: 10.1038/nm.3850. Epub 2015 Apr 20.
5
Comprehensive molecular characterization of gastric adenocarcinoma.
Nature. 2014 Sep 11;513(7517):202-9. doi: 10.1038/nature13480. Epub 2014 Jul 23.
6
Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer.
Nat Genet. 2014 Jun;46(6):573-82. doi: 10.1038/ng.2983. Epub 2014 May 11.
7
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Lancet. 2010 Aug 28;376(9742):687-97. doi: 10.1016/S0140-6736(10)61121-X. Epub 2010 Aug 19.
8
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.
Ann Oncol. 2008 Sep;19(9):1523-9. doi: 10.1093/annonc/mdn169. Epub 2008 Apr 25.
Zotero 插件